MIAMI, June 22, 2021 /PRNewswire/ -- BioReference
Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today
announced a COVID-19 testing program for U.S. based crew and
guests who cruise with Royal Caribbean Group, helping provide a
safe environment for travelers.
BioReference announced a COVID-19 testing program for U.S. based
crew and guests who cruise with Royal Caribbean Group.
Under the agreement, unvaccinated guests will be required to
undergo rapid, point-of-care PCR COVID-19 prior to embarking. These
guests will also undergo rapid, COVID-19 point-of-care testing at
the end of their voyage, before disembarking. Depending on voyage
length, testing may also take place on board, during the cruise.
All Royal Caribbean Group crew members will be required to undergo
routine laboratory-based PCR tests at regular intervals.
"Royal Caribbean Group has worked diligently with us to develop
a set of testing protocols in conjunction with other mitigation
strategies to provide the safest possible environment for all
passengers and crew," said Jon R.
Cohen, M.D., Executive Chairman of BioReference
Laboratories. "Our first in the nation custom solution for the
cruise industry was developed so that each passenger will be
tested, and results provided within 40 minutes of their arrival at
the port."
About BioReference Laboratories, Inc.
BioReference
Laboratories, Inc., is one of the largest full service specialty
laboratories in the United States
that gives healthcare providers and patients the power to make
confident healthcare decisions. With a focus on genetics, oncology,
urology and women's health, BioReference offers comprehensive test
solutions and unparalleled expertise based on a 40 year legacy of
proven science. The company is in-network with the largest health
plans in the United States, serves
approximately 19 million patients annually, operates a network of
11 laboratory locations, and is backed by a medical staff of more
than 300 M.D., D.O., Ph.D., genetic
counselors and other professional clinical and scientific
personnel. With a national footprint and niche market experience,
BioReference provides credible and innovative solutions that meet
the needs of employers, governmental agencies, educational systems,
hospitals and health systems, correctional institutions, sports
leagues, travel and leisure industries, and retail markets.
BioReference provides industry-leading custom solutions for
COVID-19, including point-of-care testing and large-scale screening
programs. https://www.bioreference.com/
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
the role and value of testing, whether the results from our
previous testing program can be successfully duplicated or deployed
in other settings or venues, whether implementing the same
strategies or other strategies will be successful in preventing the
spread of the disease or providing safety against infection to the
participants, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, and strategies. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements.
These factors include those described in the OPKO Health, Inc.
Annual Reports on Form 10-K filed and to be filed with the
Securities and Exchange Commission and in its other filings with
the Securities and Exchange Commission. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
Media Contacts:
BioReference Laboratories
Hillary
Titus, 201-406-9968
htitus@bioreference.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bioreference-laboratories-announces-first-covid-19-testing-program-for-cruise-industry-301317242.html
SOURCE BioReference Laboratories, Inc